The Pharmaceutical Journal
Vol 268 No 7196 p597-604
4 May 2002

This article
Reprint
Photocopy

News summary

Mycophenolate halts renal decline in transplant patients

Substituting mycophenolate mofetil (CellCept) for ciclosporin in kidney transplant patients can halt deteriorating kidney function, a new study shows.

Dr Christopher Dudley, Southmead Hospital, Bristol, randomly assigned 73 kidney transplant patients to treatment with mycophenolate mofetil and ciclosporin withdrawal and 70 patients to continue with ciclosporin.

He found that of those assigned to receive mycophenolate mofetil, renal function stabilised or improved in 58 per cent of patients compared with 32 per cent of patients who continued to receive ciclosporin.

The results of the Roche-sponsored study were presented at the American Transplant Congress in Washington this week.